Critical approach of blood assays measuring γ-interferon when suspecting active tuberculosis: Discussion of clinical cases;Approche critique de l'utilisation des tests sanguins mesurant l'interféron-γ lors de suspicion de tuberculose: Cas pratiques

Revue Medicale Suisse

Volumn 2, Issue 87, 2006, Pages 2620-2625

  Janssens, Jean Paul ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; RITUXIMAB;

ADULT; ANOREXIA; ARTICLE; ASSAY; ASTHENIA; ATYPICAL MYCOBACTERIUM; BLOOD EXAMINATION; CASE REPORT; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; LATENT PERIOD; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL LYMPHOCYTE; RHEUMATIC FEVER; SCREENING; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TUBERCULIN TEST; TUBERCULOSIS; WEIGHT REDUCTION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CONTACT TRACING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON TYPE II; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 33845274925     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. ** Lurati Ruiz F, Audran R, Harari A, Spertini F. Specific interferon-γ assays: A modern tool for tuberculosis diagnosis. Rev Med Suisse 2006;1042:4-7.
2. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11:195-202.
3. ** Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis:A systematic review. Lancet Infect Dis 2004;4:761-76.
4. * Nendaz MR, Perrier A. Théorème de Bayes et rapports de vraissemblance (Bayes theorem and likelihood ratios). Rev Mal Respir 2004;21:394-7.
5. * Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30.
6. Office fédéral de la santé publique. Dépistage et traitement de l'infection tuberculeuse, vaccination BCG. Forum Med Suisse 2003;3:531-9.
7. Janssens JP, Zellweger JP. Epidémiologie, clinique, et traitement de la tuberculose chez les sujets âgés. Schweiz Med Wochenschr 1999;129:80-9.
8. * Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection:An interferon-gamma-based assay using new antigens.Am J Respir Crit Care Med 2004;170:59-64.
9. ** Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357:2017-21.
10. ** Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. Contact tracing using a new T-cell-based test: Better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis 2005;9:1242-7.
11. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006;28:45-50.